Sihuan Pharmaceutical Holdings Group Ltd., headquartered in Beijing, China, announced that the Group has recently set up its Research and Development Centre in the San Francisco Bay Area in California of the United States after two years of planning.
The establishment of Sihuan Pharmaceutical’s U.S. R&D Centre is an important step on the road to the Group’s global strategic planning. As a center of global biomedical technology, the San Francisco Bay Area has a concentration of top talent and advanced concept for innovative drug R&D. The Center will make full use of local talent and contract research organizations, and primarily focus on the development of first-in-class immuno-oncology drugs, including small molecule drugs and large molecule biological drugs such as antibodies and fusion protein drugs. All the researchers and consultants of the Center are senior scientists with extensive experiences in innovative drug R&D. There are multiple projects under development currently.
Sihuan Pharmaceutical’s U.S. R&D Centre will work closely with and complement the Group’s existing R&D platforms. On one hand, after finishing preclinical research of the drugs in the U.S., the Center will work with the Group’s R&D platforms in China, in where sample production and clinical development will be conducted, in order to achieve effective resources utilization. On the other hand, the Center will make flexible adjustments to its R&D strategy based on government policies, regulations and the market environment.
For instance, the Group plans to promote internationalization of its products through commencing clinical trials and registration process in the U.S. and China simultaneously. Meanwhile, it is expected to accelerate marketization of the products in China.